Dicerna Closes $25M Series B

Premium

Dicerna Pharmaceuticals said that it has closed a $25 million Series B round of financing, which will provide the company with the money needed to advance its lead oncology drug-development program, as well as other pipeline efforts.

Dicerna said it would also use the funds to further develop its delivery technologies.

The round was led by a new investor, Domain Associates, and included existing investors Oxford Bioscience Partners, Skyline Ventures, and Abingworth.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.